Hansa Biopharma AB (publ)

OM:HNSA Stock Report

Market Cap: SEK 2.0b

Hansa Biopharma Valuation

Is HNSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HNSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HNSA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HNSA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HNSA?

Key metric: As HNSA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HNSA. This is calculated by dividing HNSA's market cap by their current revenue.
What is HNSA's PS Ratio?
PS Ratio10.7x
SalesSEK 189.39m
Market CapSEK 2.02b

Price to Sales Ratio vs Peers

How does HNSA's PS Ratio compare to its peers?

The above table shows the PS ratio for HNSA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.9x
DVYSR Devyser Diagnostics
11x31.3%SEK 2.2b
EGTX Egetis Therapeutics
27.6x81.7%SEK 1.9b
CRNO B Cereno Scientific
20.5x-171.4%SEK 1.4b
PROB Probi
4.7x5.3%SEK 2.9b
HNSA Hansa Biopharma
10.7x47.3%SEK 2.0b

Price-To-Sales vs Peers: HNSA is good value based on its Price-To-Sales Ratio (10.7x) compared to the peer average (15.9x).

Price to Sales Ratio vs Industry

How does HNSA's PS Ratio compare vs other companies in the SE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.5x61.1%US$27.20m
SPRINT Sprint Bioscience
1.7x27.6%US$9.38m
PMDS PMD Device Solutions
0.8x62.0%US$3.07m
GEAN Genetic Analysis
1.5xn/aUS$2.63m
HNSA 10.7xIndustry Avg. 12.2xNo. of Companies6PS0816243240+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HNSA is good value based on its Price-To-Sales Ratio (10.7x) compared to the Swedish Biotechs industry average (11.8x).

Price to Sales Ratio vs Fair Ratio

What is HNSA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HNSA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.7x
Fair PS Ratio9.8x

Price-To-Sales vs Fair Ratio: HNSA is expensive based on its Price-To-Sales Ratio (10.7x) compared to the estimated Fair Price-To-Sales Ratio (9.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HNSA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 29.84
SEK 99.25
+232.6%
52.5%SEK 175.00SEK 46.00n/a4
Nov ’25SEK 36.68
SEK 100.00
+172.6%
51.5%SEK 175.00SEK 46.00n/a4
Oct ’25SEK 39.56
SEK 100.00
+152.8%
51.5%SEK 175.00SEK 46.00n/a4
Sep ’25SEK 55.20
SEK 100.00
+81.2%
51.5%SEK 175.00SEK 46.00n/a4
Aug ’25SEK 39.96
SEK 100.00
+150.3%
51.5%SEK 175.00SEK 46.00n/a4
Jul ’25SEK 46.00
SEK 105.00
+128.3%
44.7%SEK 175.00SEK 57.00n/a4
Jun ’25SEK 49.64
SEK 105.00
+111.5%
44.7%SEK 175.00SEK 57.00n/a4
May ’25SEK 28.94
SEK 105.00
+262.8%
44.7%SEK 175.00SEK 57.00n/a4
Apr ’25SEK 29.10
SEK 112.50
+286.6%
36.9%SEK 174.00SEK 57.00n/a4
Mar ’25SEK 32.26
SEK 112.50
+248.7%
36.9%SEK 174.00SEK 57.00n/a4
Feb ’25SEK 34.00
SEK 91.00
+167.6%
58.0%SEK 173.00SEK 16.00n/a5
Jan ’25SEK 26.20
SEK 108.33
+313.5%
57.1%SEK 195.00SEK 16.00n/a6
Dec ’24SEK 25.50
SEK 123.00
+382.4%
47.3%SEK 195.00SEK 16.00n/a6
Nov ’24SEK 23.10
SEK 123.00
+432.5%
47.3%SEK 195.00SEK 16.00SEK 36.686
Oct ’24SEK 34.40
SEK 167.50
+386.9%
22.4%SEK 224.00SEK 109.00SEK 39.566
Sep ’24SEK 43.82
SEK 167.50
+282.2%
22.4%SEK 224.00SEK 109.00SEK 55.206
Aug ’24SEK 54.30
SEK 167.50
+208.5%
22.4%SEK 224.00SEK 109.00SEK 39.966
Jul ’24SEK 43.46
SEK 168.50
+287.7%
23.8%SEK 224.00SEK 112.00SEK 46.006
Jun ’24SEK 45.74
SEK 168.50
+268.4%
23.8%SEK 224.00SEK 112.00SEK 49.646
May ’24SEK 50.35
SEK 171.29
+240.2%
19.8%SEK 224.00SEK 128.00SEK 28.947
Apr ’24SEK 51.25
SEK 176.83
+245.0%
22.8%SEK 241.00SEK 128.00SEK 29.106
Mar ’24SEK 53.85
SEK 176.83
+228.4%
22.8%SEK 241.00SEK 128.00SEK 32.266
Feb ’24SEK 61.45
SEK 177.60
+189.0%
24.9%SEK 245.00SEK 128.00SEK 34.005
Jan ’24SEK 49.22
SEK 176.20
+258.0%
26.0%SEK 245.00SEK 121.00SEK 26.205
Dec ’23SEK 54.50
SEK 176.20
+223.3%
26.0%SEK 245.00SEK 121.00SEK 25.505
Nov ’23SEK 53.75
SEK 186.50
+247.0%
25.6%SEK 245.00SEK 121.00SEK 23.106

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Swedish Orphan Biovitrum

SEK 103.1b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 300.20

7D

-8.5%

1Y

24.2%

Corline Biomedical

SEK 139.3m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.48

7D

-7.7%

1Y

-44.1%

Camurus

SEK 32.1b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 546.00

7D

-12.2%

1Y

22.4%